Resistin-like β (RETNLB) is a significant member of the resistin family of cytokines, characterized by its involvement in the regulation of inflammatory responses within the body. This protein, through its expression in tissues such as the lungs, adipose tissue, and gastrointestinal tract, plays a crucial role in orchestrating the body's immune response to various stimuli. RETNLB's primary function revolves around its capacity to influence the inflammatory cascade, thereby participating in the complex interplay between pro-inflammatory and anti-inflammatory signals. It exerts its effects by binding to specific receptors on the surfaces of target cells, initiating a series of intracellular signaling pathways that ultimately lead to the transcription of inflammation-related genes. The regulation of RETNLB activity is essential for maintaining homeostasis and preventing the dysregulation of inflammatory processes, which can contribute to the pathogenesis of various diseases.
The inhibition of RETNLB involves multiple mechanisms that serve to downregulate its expression or activity, thereby mitigating its pro-inflammatory effects. These mechanisms can include the suppression of RETNLB transcription through the interference with transcription factors or signaling pathways that promote its expression. Additionally, post-translational modifications of RETNLB that are crucial for its activity, such as glycosylation or cleavage, can be targeted to reduce its stability or secretion. The interaction between RETNLB and its receptors on target cells can also be inhibited, preventing the initiation of downstream signaling cascades responsible for the inflammatory response. Furthermore, the modulation of the immune system's regulatory elements, such as specific microRNAs or other non-coding RNAs, presents another avenue through which RETNLB activity can be attenuated. These inhibitory mechanisms are vital for controlling the extent of the inflammatory response mediated by RETNLB, ensuring that it remains within physiological limits to prevent the development of inflammatory-related conditions. Through understanding these processes, the regulation of RETNLB activity emerges as a critical aspect of maintaining immune homeostasis and preventing inflammatory dysregulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMP-activated protein kinase (AMPK), which can regulate the secretion and function of adipokines like RETNLB. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
As a PPARγ agonist, rosiglitazone can modulate the expression of various adipokines, potentially affecting RETNLB's activity. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Similar to rosiglitazone, pioglitazone acts on PPARγ and may alter RETNLB levels or activity as part of adipocyte regulation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin can modulate inflammatory pathways and adipokine expression, which may influence RETNLB signaling. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
By antagonizing PPARγ, GW9662 can impact adipokine regulation, possibly affecting RETNLB's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This MEK inhibitor can disrupt downstream signaling of various cytokines and growth factors, potentially altering RETNLB's effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, LY294002 can affect multiple signaling pathways, potentially including those involving RETNLB. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can affect inflammatory signaling, which might influence RETNLB activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
By inhibiting p38 MAPK, SB203580 can affect inflammatory responses and adipokine regulation, potentially impacting RETNLB. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, rapamycin can affect adipocyte function and cytokine production, which may in turn influence RETNLB. | ||||||